The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
CCL
Vol.
35
No.
10
October 26, 2012
- Ultrasound Shown to be Superior Diagnostic Compared to Mammography in Women Ages 30-39
- Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial
- New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years
- Two Phase II Trials Display Ramucirumab Potential Efficacy
- Gene Variant Associated With 44 Percent Cancer Risk Reduction
- Five-Fold Increase in Chordoma Risk Linked to Common Gene Variant
- HCT Survivors More Likely To Show Heart Disease Risk Factors
- PV-10 Produces 51 Percent Response Rate in Phase II Trial
- Folic Acid, Vitamins B6 and 12 Do Not Affect Colorectal Adenoma Risk
- Three Studies Test Oncotype DX In Breast and Colon Cancers
- NCI-Approved CTEP Trials For the Month of October
- FDA Approves Abraxane And Alimta for NSCLC
CCL
Vol.
35
No.
11
November 30, 2012
- SBRT Delivers Higher Overall Survival Rates Compared to Conventional Radiation Therapy
- Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease
- Phase III Trial of Avastin and Temozolomide Shows Reduced Risk of Cancer Progression
- Abraxane and Gemcitabine Improves Overall Survival
- Study Uncovers New Mechanism In Class of Chemotherapy Drugs
- Adjuvant Radiation Treatment Shows Improved Survival In Elderly, Early-Stage Patients
- Genetic Test Identifies Patients With High Risk of Mortality
- Memantine Can Delay Onset Of Cognitive Function Decline
- Doxepin Rinse Reduces Pain In Radiation Therapy Patients
- Zaltrap Receives Positive Opinion For European Market From CHMP
- NCI-Approved CTEP Trials For the Month of November